Journal of Clinical Oncology, Vol 10, 1119-1123, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

DT Sleijfer, RA Janssen, J Buter, EG de Vries, PH Willemse and NH Mulder
Department of Medical Oncology, University Hospital, Groningen, The Netherlands.

PURPOSE: A single-institution phase II study was undertaken to evaluate the efficacy and toxicity of interleukin-2 (IL-2) administered by subcutaneous injection. PATIENTS AND METHODS: Twenty-seven unselected patients (15 male) with a mean age of 60 years (range, 42 to 76 years) who had advanced renal cell cancer were treated as outpatients. IL-2 was given once a day, 5 days per week for 6 weeks. During the first 5- day cycle, 18 x 10(6) IU was given once daily; in the following cycles, the doses in the first 2 days were reduced to 9 x 10(6) IU. After a 3- week rest period, treatment was repeated in patients who had a response or stable disease (SD). To prevent pyretic reactions, patients also received acetaminophen (250 to 500 mg given orally every 4 to 6 hours). RESULTS: After 6 weeks, 26 patients were assessable for response. Two patients (8%) had a complete remission (CR), four (15%) had a partial remission (PR), and 13 (50%) had SD. A second cycle of 6 weeks was given to 19 patients; one patient with a PR and six with SD showed progression. Duration of the CR was 17+ and 19+ months, and length of the PR was 2, 8, 11, and 11+ months. The median survival of the patients who were nonresponders and responders was 10 and 20+ months, respectively, and for all patients was 13 months. One patient died as a result of myocardial infarction and brain stem ischemia. Systemic side effects in the other patients were tolerated and accepted, and included transient inflammation and local induration at the injection sites, fever and chills, and nausea. CONCLUSION: Subcutaneous IL-2 is clinically active, has an acceptable toxicity, and can be given to patients with concomitant disease.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. F. McDermott Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 716s - 720s. [Abstract] [Full Text] [PDF]

				M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]

				D. F. McDermott, M. M. Regan, J. I. Clark, L. E. Flaherty, G. R. Weiss, T. F. Logan, J. M. Kirkwood, M. S. Gordon, J. A. Sosman, M. S. Ernstoff, et al. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., January 1, 2005; 23(1): 133 - 141. [Abstract] [Full Text] [PDF]

				J. Atzpodien, H. Kirchner, U. Jonas, L. Bergmann, H. Schott, H. Heynemann, P. Fornara, S.A. Loening, J. Roigas, S.C. Muller, et al. Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) J. Clin. Oncol., April 1, 2004; 22(7): 1188 - 1194. [Abstract] [Full Text] [PDF]

				J. C. Yang, R. M. Sherry, S. M. Steinberg, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, D. E. White, et al. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer J. Clin. Oncol., August 15, 2003; 21(16): 3127 - 3132. [Abstract] [Full Text] [PDF]

				J. I. Clark, T. M. Kuzel, T. M. Lestingi, S. G. Fisher, P. Sorokin, B. Martone, M. Viola, and J. A. Sosman A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon {alpha}-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population Ann. Onc., April 1, 2002; 13(4): 606 - 613. [Abstract] [Full Text] [PDF]

				L. Capuron, A. Ravaud, and R. Dantzer Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-{alpha} Treatments in Cancer Patients Psychosom Med, May 1, 2001; 63(3): 376 - 386. [Abstract] [Full Text] [PDF]

				L. Capuron, A. Ravaud, and R. Dantzer Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy J. Clin. Oncol., May 10, 2000; 18(10): 2143 - 2151. [Abstract] [Full Text] [PDF]

				G. C. de Gast, H.-J. Klumpen, F. A. Vyth-Dreese, M.-J. Kersten, N. C. V. Verra, J. Sein, D. Batchelor, W. J. Nooijen, and J. H. Schornagel Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon {{alpha}} in Progressive Metastatic Melanoma and Renal Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1267 - 1272. [Abstract] [Full Text]

				J. I. Clark, E. R. Gaynor, B. Martone, S. C. Budds, R. Manjunath, R. C. Flanigan, W. B. Waters, and J. A. Sosman Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-{{alpha}} in Patients with Advanced Renal Cell Carcinoma Clin. Cancer Res., September 1, 1999; 5(9): 2374 - 2380. [Abstract] [Full Text] [PDF]

				M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, et al. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 J. Clin. Oncol., July 1, 1999; 17(7): 2105 - 2105. [Abstract] [Full Text] [PDF]

				J. C. Nesbitt, E. R. Soltero, C. P. N. Dinney, G. L. Walsh, D. S. Schrump, D. A. Swanson, L. L. Pisters, K. D. Willis, and J. B. Putnam Jr Surgical Management of Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus Ann. Thorac. Surg., June 1, 1997; 63(6): 1592 - 1599. [Abstract] [Full Text]